

Page 66, line 19, change "... ser pro asp gln glu glu gln" to --... ser pro asp glu gln glu gln--.

Page 67, line 4, change the "E" at the end of the line to --G--.

Page 68, line 6, change "val phe cys met phe cys met phe tyr ..." to --val phe cys met phe tyr ...--.

Replace the Sequence Listing (pages 1-34) filed on June 22, 2000, with the attached Sequence Listing (pages 1-36).

REMARKS

The Office has indicated that the application does not comply with the requirements of 37 C.F.R. §§ 1.821 - 1.825. Applicants have amended the application to replace the Sequence Listing filed on June 22, 2000, with the corrected Sequence Listing that is attached hereto. A copy of the Sequence Listing in computer readable form is also attached, accompanied by a verified statement that the paper and computer readable copies of the Sequence Listing are the same and that no new matter has been added. All of the sequences in the attached Sequence Listing find full support in the application as originally filed. Applicants submit that the requirements of 37 C.F.R. §§ 1.821 - 1.825 have now been met.

Applicants have amended the specification at pages 6 and 14 to refer to specific residues recited in the new Sequence Listing. Support for these amendments is inherent in the sequences as originally disclosed in the specification, and thus no new matter is added.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

Applicants have also amended the specification to correct typographical errors on pages 66-68. Specifically, three amendments are made, all three of which are fully supported by the specification as originally filed.

The first amendment corrects a typographical error in SEQ ID NO. 54, in which the identities of residues 19 and 20 were transposed (*i.e.*, the sequence gln-glu was typed rather than the sequence glu-gln). Support for the corrected sequence for SEQ ID NO. 54 comes from the specification on page 66, lines 1-18 and page 67, lines 1-4. In particular, the sequence referred to as SEQ ID NO. 54 is indicated in the specification (page 66, lines 16-18) as the translation product of the nucleotide sequence disclosed on page 66, lines 5-15. Translation of that nucleotide sequence results in an amino acid sequence having a glutamic acid at residue 19 and a glutamine at residue 20, not a glutamine at residue 19 and a glutamic acid at residue 20. The correct sequence at residues 19 and 20 is recited in the one-letter amino acid sequence following SEQ ID NO. 54, which is currently assigned SEQ ID NO. 61.

The second amendment corrects a typographical error in the sequence now assigned SEQ ID NO. 61. In this sequence, the final residue was originally disclosed on page 67, line 4, as "E" (glutamic acid). However, it should have been depicted as "G" (glycine). Support for the corrected sequence for SEQ ID NO. 61 comes from the specification on page 66, lines 1-18, and the last residue of SEQ ID NO. 54. That is, like SEQ ID NO. 54, the sequence of current SEQ ID NO. 61 is the sequence of the translation product of SEQ ID NO. 51.

Applicants respectfully submit that it was their initial intent to depict the translation product of SEQ ID NO. 51 two times following the disclosure of SEQ ID NO. 51, once using the three-letter amino acid code (SEQ ID NO. 54), and once using the one-letter amino acid code

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

(current SEQ ID NO. 61).¹ However, unintentional typographical errors resulted in the two amino acid sequences having different sequences. Applicants have now corrected those typographical errors, resulting in two sequence identifiers (SEQ ID NO. 54 and SEQ ID NO. 61) having the same sequence. If the Examiner would prefer that Applicants delete one of these two sequences from the Sequence Listing (or the Sequence Listing and the specification), Applicants will be more than willing to do so upon the Examiner's request.

The third amendment corrects a typographical error in SEQ ID NO. 55. In SEQ ID NO. 55, as originally disclosed in the specification, three amino acids were unintentionally repeated. Specifically, the tri-peptide sequence cys-met-phe, which are residues 119, 120, and 121 of the translation product of SEQ ID NO. 52, are repeated as residues 122, 123, and 124 in SEQ ID NO. 55. This Amendment deletes the repeated residues in SEQ ID NO. 55. Support for the corrected sequence of SEQ ID NO. 55 comes from the specification, as originally filed, on page 67, lines 11-30 (SEQ ID NO. 52), which, when properly translated, results in the corrected sequence of SEQ ID NO. 55. Support also comes from current SEQ ID NO. 62, which correctly depicts the translation product of SEQ ID NO. 52.

Applicants respectfully submit that it was their initial intent to depict the translation product of SEQ ID NO. 52 two times following the disclosure of SEQ ID NO. 52, once using the three-letter amino acid code (SEQ ID NO. 55), and once using the one-letter amino acid code (current SEQ ID NO. 62). However, unintentional typographical errors in SEQ ID NO. 55 resulted in the two amino acid sequences having different sequences. Applicants have now

¹ This intent is further evident from the amino acid sequences following SEQ ID NO. 53 (see pages 69-70), where the translation product sequence is depicted twice, once in three-letter code and once in one-letter code).

corrected those typographical errors, resulting in two sequence identifiers (SEQ ID NO. 55 and SEQ ID NO. 62) having the same sequence. If the Examiner would prefer that Applicants delete one of these two sequences from the Sequence Listing (or the Sequence Listing and the specification), Applicants will be more than willing to do so upon the Examiner's request.

In view of the explanation presented above, Applicants respectfully submit that no new matter is added by this Amendment or the attached Sequence Listing. Accordingly, Applicants respectfully request that the Office enter this Amendment and Sequence Listing, and examine this application on the merits.

If the Examiner believes anything further is necessary to place this application in condition for examination, he is invited to contact Applicants' undersigned representative at the telephone number or e-mail address below.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Matthew T. Latimer
Reg. No. 44,024
(202) 408-4495
matthew.latimer@finnegan.com

Date: February 5, 2001

Attachments:

Sequence Listing (paper and computer readable copies)
Statement in Support of Filing
Copy of Notice to Comply